Novimmune's NI-0501 accepted onto's EMA's PRIME scheme

6 June 2016
2019_biotech_test_vial_discovery_big

Privately-held Swiss biotech Novimmune has announced that its lead program, NI-0501, has been declared eligible for the PRIME (PRIority MEdicine) scheme of the European Medicines Agency (EMA) for the treatment of primary hemophagocytic lymphohistiocytosis (HLH).

The company’s compound is currently in Phase II/III of clinical development to treat HLH, a life-threatening disease of severe hyperinflammation which mainly occurs in children.

Launched only in March of this year, the PRIME scheme has been initiated by the EMA to enhance support for the development of medicines that target an unmet medical need, helping patients to benefit as early as possible from therapies that may significantly improve their health condition or quality of life.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology